Navigation Links
SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
Date:9/24/2013

ST. LOUIS, Sept. 24, 2013 /PRNewswire/ -- SAGE Labs, Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, announced today that it has entered into a partnership and licensing agreement with Caribou Biosciences, Inc. (Caribou Bio) for key intellectual property related to the CRISPR/Cas9 genome editing system.

Under the agreement, SAGE Labs will gain exclusive rights to Caribou Bio's intellectual property to produce and sell genetically engineered rats, and will gain non-exclusive rights for mouse and rabbit models.  The Cas9 system will complement SAGE's Zinc Finger Nuclease (ZFN) technology, allowing SAGE to offer customers access to novel animal models of human disease, as well as reduced turnaround times for its custom model creation platform, SAGEspeed®.

"SAGE Labs is the leader in creation of next-generation research models. As such, it is important to have access to key technologies needed to perform complex genome engineering projects," commented Dr. David Smoller, CEO of SAGE Labs. "Using Cas9 allows us to provide our customers with enhanced models that provide the most translational value for their research."

"We believe the Cas9 system will become very important in the creation of new models of human disease, both in vitro and in vivo," commented Dr. Rachel Haurwitz, CEO of Caribou Bio. "SAGE Labs' track record as a market leader in commercializing in vivo technologies will enable them to use Cas9-based engineering to bring innovative, high-quality engineered research models to the marketplace."

Please see www.sageresearchlabs.com for further details.

About SAGE Labs

SAGE® Labs is a world-class provider of next-generation research models and transgenic support services. Using proprietary platform technologies, such as Zinc Finger Nucleases (ZFN) and the CRISPR/Cas9 system for genome engineering, SAGE produces complex in vivo research models in half the time as models produced using conventional technologies. For more information, visit http://www.sageresearchlabs.com.

About Caribou Bio

Caribou Bio specializes in the research and development of technologies for cellular engineering and analysis. Caribou Bio's technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. Caribou Bio's lead technology is the Cas9 enzyme, a highly efficient and easy to use genome editing platform that does not require unique protein development.

Media Contact:
Phil Simmons
(314) 313-7847
Phil.Simmons@sageresearchlabs.com

 


'/>"/>
SOURCE SAGE Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. LABS, Inc. Earns AABB Accreditation for Donor Testing
2. LABS, Inc. Among Colorados Top Private Companies
3. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
4. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
5. Genomatica Licenses TeselaGen Software for DNA Design
6. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
7. SRI International Licenses Bed Bug Detection Technology to Redcoat, a Virginia-Based Start-Up Company
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
10. Syngenta Licenses Plant Sensory Systems' Technology
11. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... 23, 2017 According to a report by ... market is fragmented due to the presence of a large pool of ... Thermo Fisher , and Sigma-Aldrich, compete with each other in this ... held more than 76% of this market in 2016.  ... As of now, a large ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... , March 22, 2017 Good Start ... it has eclipsed the 130 million covered lives mark ... Shield of Texas . With newly ... Company continues to enjoy strong payor acceptance based on ... clinical programs and genetic counseling, its industry-leading customer care ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
Breaking Biology News(10 mins):